HomeNewsIndiaAntidepressant sales in India surge 64% in post-Covid years: Report

Antidepressant sales in India surge 64% in post-Covid years: Report

The data revealed that a combination of Escitalopram and Clonazepam was on top of the list, seeing an increase of 59.35% in sales since 2020.

December 30, 2024 / 13:27 IST
Story continues below Advertisement
Mental health issues
In 2020, the market for these medications was valued at ₹1,540 crore across India. By November 2024, that figure rose to ₹2,536 crore.

The Indian mind is in throes of a long covid it seems, as the sale of antidepressant and anti-anxiety pills has boomed over 64 percent since the pandemic phased out, according to a report by the Times of India.

In 2020, the domestic market for these medicines was valued at Rs 1,540 crore and, by November 2024, it surged to Rs 2,536 crore, clocking a compound annual growth rate (CAGR) of 13 percent. The market grew by 64 percent in four years, shows data by Pharmarack, which monitors 17 leading Indian pharmaceutical companies accounting for over half of the industry.

Story continues below Advertisement

A combination of Escitalopram and Clonazepam was topped the list with a 59.35 growth in sales since 2020. Escitalopram is used to treat depression and anxiety disorders, boosts serotonin levels in the brain, while Clonazepam is prescribed to manage anxiety, panic attacks, and seizures by calming the central nervous system.

It is found that the sales of Sertraline, used to treat depression, obsessive-compulsive disorder, and post-traumatic stress disorder, grew 48.2 percent in the same period.